Insights Into Acute Lymphoblastic Leukemia (ALL) 2024

Perspectives of community physicians on the treatment of ALL

National – June 24, 2024

Faculty Chair

Michael R. Grunwald, MD, FACP

Atrium Health Levine Cancer Institute, Charlotte, NC, USA

More Information

  • Virtual series
  • California, Nevada, Texas, New Mexico, Indiana, Ohio, New York, New Jersey, Maryland

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of ALL
  • Disease state and data presentations were developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies were obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in Insights Into Acute Lymphoblastic Leukemia (ALL) 2024.

Complete the form below to receive additional information.